Design, Science and Technology

 

Moderna's newest vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration.

 

Moderna’s newest Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company recently stated. The updated shot is designed to target omicron subvariant XBB.1.5, but the results suggest that the injection may still be effective against newer variants of the virus that are gaining ground nationwide. That includes Eris and another variant nicknamed Fornax, both of which are also descendants of the omicron virus variant.

 

Read the full article at: www.cnbc.com

Via Juan Lama, Dr. Stefan Gruenwald

Participants in the trial must be between the ages of 18 and 50 and not diagnosed with HIV.  Moderna is set to start human trials for its experimental mRNA HIV vaccine as early as Thursday, the first time such a trial has ever been conducted. 

 

The big picture: "There's a pressing need for new ways to prevent infection from viruses like HIV and influenza that conventional vaccines have struggled to address and to treat rare genetic diseases and cancers that kill millions each year," Axios' Alison Snyder writes. "Vaccines and therapies based on messenger RNA (mRNA) hold promise as a solution."

 

Read the full article at: www.axios.com

Via Juan Lama, Dr. Stefan Gruenwald